Scientific and Medical Advisory Board

Scientific and Medical Advisory Board

Douglas Blayney, MD
Principal investigator, study 105 & 106

– Founding and former member of the NCCN Myeloid Growth Factor guideline panel.

– Former president of the American Society for Clinical Oncology.

– Professor of Medicine (Oncology) at Stanford University.

 

Jeffrey Crawford, MD
DSMB Chairman, Study 105 & 106

– Chairman of NCCN guidelines for neutropenia management in US.

– Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), leading to FDA approval.

– Professor at Duke University.

 

Yuankai Shi, MD
Principal investigator in China, study 105 & 106

– Chairman of the NCCN guidelines for neutropenia management in China.

– Director of Oncology Department at Cancer Hospital Chinese Academy of Medical Sciences.

 

 

David Ettinger, MD
SAB member, Study 103

– Chairman of NCCN NSCLC guideline panel; Board of Directors, NCCN guideline.

– Alex Grass Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 

 

Yan Sun, MD
Principal investigator in China, Study 103

– Chairman of the NCCN guidelines for NSCLC in China.

– Co-founder of the Steering Committee of the Chinese Society of Clinical Oncology(CSCO).

– GCP center director at Cancer Hospital Chinese Academy of Medical Sciences.

 

Klaus Ley, PhD
KOL of Neutropenia mechanism

– 30 years of experience in neutrophil research

– Published more than 300 papers in peer-review journals and writes review articles on neutrophils for Science Magazine.

– Professor at La Jolla institute of Immunology and Allergy.